Related references
Note: Only part of the references are listed.Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players
Patrice Marques et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Sven Francque et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview
Carlos Villarroel-Vicente et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Liver-targeting drugs and their effect on blood glucose and hepatic lipids
Amalia Gastaldelli et al.
DIABETOLOGIA (2021)
The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance
David Aguilar-Recarte et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice
Zheng Li et al.
PHARMACOLOGICAL RESEARCH (2020)
PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice
Yaping Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Design, synthesis, and biological evaluation of novel dual PPARα/δ agonists for the treatment of T2DM
Qiang Ren et al.
BIOORGANIC CHEMISTRY (2020)
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Nathalie Percie du Sert et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents
Zheng Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Systemic Inflammation in Metabolic Syndrome: Increased Platelet and Leukocyte Activation, and Key Role of CX3CL1/CX3CR1 and CCL2/CCR2 Axes in Arterial Platelet-Proinflammatory Monocyte Adhesion
Patrice Marques et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Polycerasoidol, a Natural Prenylated Benzopyran with a Dual PPARα/PPARγ Agonist Activity and Anti-inflammatory Effect
Almudena Bermejo et al.
JOURNAL OF NATURAL PRODUCTS (2019)
Contribution of genetics to visceral adiposity and its relation to cardiovascular and metabolic disease
Torgny Karlsson et al.
NATURE MEDICINE (2019)
PPAR beta/delta: A Key Therapeutic Target in Metabolic Disorders
Xavier Palomer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Distinct but complementary contributions of PPAR isotypes to energy homeostasis
Vanessa Dubois et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Structural basis for specific ligation of the peroxisome proliferator-activated receptor δ
Chyuan-Chuan Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
CD206+ M2-like macrophages regulate systemic glucose metabolism by inhibiting proliferation of adipocyte progenitors
Allah Nawaz et al.
NATURE COMMUNICATIONS (2017)
M2-like macrophages in the fibrotic liver protect mice against lethal insults through conferring apoptosis resistance to hepatocytes
Li Bai et al.
SCIENTIFIC REPORTS (2017)
Liver immunology and its role in inflammation and homeostasis
Mark W. Robinson et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2016)
The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges
Wai San Cheang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Hepatic lipase deficiency produces glucose intolerance, inflammation and hepatic steatosis
Irene Andres-Blasco et al.
JOURNAL OF ENDOCRINOLOGY (2015)
Inflammation and macrophage modulation in adipose tissues
Victoria J. Vieira-Potter
CELLULAR MICROBIOLOGY (2014)
Minireview: Challenges and Opportunities in Development of PPAR Agonists
Matthew B. Wright et al.
MOLECULAR ENDOCRINOLOGY (2014)
The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility
Shuai Zhang et al.
NUTRITION & METABOLISM (2014)
Role of Metformin in Suppressing 1,2-Dimethylhydrazine-Induced Colon Cancer in Diabetic and Non-Diabetic Mice: Effect on Tumor Angiogenesis and Cell Proliferation
Dalia K. Zaafar et al.
PLOS ONE (2014)
Visceral Adiposity and the Risk of Metabolic Syndrome Across Body Mass Index
Ravi V. Shah et al.
JACC-Cardiovascular Imaging (2014)
Peroxisome proliferator-activated receptor a activation attenuates the inflammatory response to protect the liver from acute failure by promoting the autophagy pathway
M. Jiao et al.
CELL DEATH & DISEASE (2014)
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects
Robert S. Rosenson et al.
AMERICAN HEART JOURNAL (2012)
The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update
Hanrui Zhang et al.
BASIC RESEARCH IN CARDIOLOGY (2012)
Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism
Mi Young Lee et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2012)
Activation of peroxisome proliferator-activated receptor-β/-δ (PPARβ/δ) prevents endothelial dysfunction in type 1 diabetic rats
Ana Maria Quintela et al.
FREE RADICAL BIOLOGY AND MEDICINE (2012)
Retinoid X Receptor Agonists Impair Arterial Mononuclear Cell Recruitment through Peroxisome Proliferator-Activated Receptor-γ Activation
Maria-Jesus Sanz et al.
JOURNAL OF IMMUNOLOGY (2012)
Peroxisome Proliferator-Activated Receptors (PPARs) Have Multiple Binding Points That Accommodate Ligands in Various Conformations: Phenylpropanoic Acid-Type PPAR Ligands Bind to PPAR in Different Conformations, Depending on the Subtype
Naoyuki Kuwabara et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
PPARs at the crossroads of lipid signaling and inflammation
Walter Wahli et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2012)
Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes
Fredrick L. Dunn et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2011)
Selective peroxisome proliferator-activated receptor gamma (PPAR gamma) modulation as a strategy for safer therapeutic PPAR gamma activation
Linda Slanec Higgins et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2010)
Trans- but Not Cis-Resveratrol Impairs Angiotensin-II-Mediated Vascular Inflammation through Inhibition of NF-κB Activation and Peroxisome Proliferator-Activated Receptor-γ Upregulation
Cristina Rius et al.
JOURNAL OF IMMUNOLOGY (2010)
The metabolic syndrome
Robert H. Eckel et al.
LANCET (2010)
Activation of PPARβ/δ inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release
Laura Piqueras et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Suppression of pro-inflammatory adhesion molecules by PPAR-δ in human vascular endothelial cells
Yanbo Fan et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus
Hae Jin Kim et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Integration of metabolism and inflammation by lipid-activated nuclear receptors
Steven J. Bensinger et al.
NATURE (2008)
A critical role for TNFα in the selective attachment of mononuclear leukocytes to angiotensin-II-stimulated arterioles
Teresa Mateo et al.
BLOOD (2007)
The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk
Calin Popa et al.
JOURNAL OF LIPID RESEARCH (2007)
Activation of PPAR beta/delta induces endothelial cell proliferation and angiogenesis
Laura Piqueras et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARγ agonists
Elodie Blanc-Delmas et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
Examination of the effects of poly(N-vinylpyrrolidinone) hydrogels in direct and indirect contact with cells
LE Smith et al.
BIOMATERIALS (2006)
PPARδ regulates glucose metabolism and insulin sensitivity
CH Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Peroxisome proliferator-activated receptors and inflammation
Leonardo A. Moraes et al.
PHARMACOLOGY & THERAPEUTICS (2006)
Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice
MC Carmona et al.
INTERNATIONAL JOURNAL OF OBESITY (2005)
Nuclear factor κB:: a potential therapeutic target in atherosclerosis and thrombosis
C Monaco et al.
CARDIOVASCULAR RESEARCH (2004)
Obesity, metabolic syndrome, and cardiovascular disease
SM Grundy
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Evaluation of liver function in type 2 diabetic patients during clinical trials - Evidence that rosiglitazone does not cause hepatic dysfunction
HE Lebovitz et al.
DIABETES CARE (2002)
Cyclic AMP regulation of neutrophil apoptosis occurs via a novel protein kinase A-independent signaling pathway
MC Martin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists
JM Olefsky
JOURNAL OF CLINICAL INVESTIGATION (2000)